ARS Pharmaceuticals Full Year 2024 Earnings: Beats Expectations

Simply Wall St

ARS Pharmaceuticals (NASDAQ:SPRY) Full Year 2024 Results

Key Financial Results

  • Revenue: US$89.1m (up by US$89.1m from FY 2023).
  • Net income: US$8.00m (up from US$54.4m loss in FY 2023).
  • Profit margin: 9.0% (up from net loss in FY 2023). The move to profitability was driven by higher revenue.
  • EPS: US$0.083 (up from US$0.57 loss in FY 2023).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

NasdaqGM:SPRY Earnings and Revenue Growth March 21st 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

ARS Pharmaceuticals Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates.

Looking ahead, revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are up 21% from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We've done some analysis and you can see our take on ARS Pharmaceuticals' balance sheet.

Valuation is complex, but we're here to simplify it.

Discover if ARS Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.